1)Hart RG, Benavente O, McBride R, et al : Antithrombotic therapy to prevent stroke in patients with atrial fibrillation : a meta-analysis. Ann Intern Med 131:492-501,1999
2)河野珠美,大木元明義,青野潤大,他:80歳を超える高齢者に対するダビガトランによる抗凝固療法の検討.日老医誌 51:350-355,2014
3)松野一彦,宇佐美貴之,畑瀬正尚,他:経口抗トロンビン薬のモニター.臨病理62:958-964,2014
4)Baglin T : The role of the laboratory in treatment with new oral anticoagulants. J Thromb Haemost 11(Suppl1):122-128,2013
5)Douxfils J, Mullier F, Robert S, et al : Impact of dabigatran on a large panel of routine or specific coagulation assays. Laboratory recommendations for monitoring of dabigatran etexilate. Thromb Haemost 107:985-997,2012
6)宇佐美貴之,松野一彦,重村雅彦,他:Hemoclot thrombin inhibitors assayを用いた血中ダビガトラン濃度の測定.日検血会誌(印刷中)
7)Douxfils J, Dogné JM, Mullier F, et al : Comparison of calibrated dilute thrombin time and aPTT tests with LC-MS/MS for the therapeutic monitoring of patients treated with dabigatran etexilate. Thromb Haemost 110:543-549,2013
8)Douxfils J, Mullier F, Loosen C, et al : Assessment of the impact of rivaroxaban on coagulation assays : laboratory recommendations for the monitoring of rivaroxaban and review of the literature. Thromb Res 130:956-966,2012